CapWealth Advisors LLC Has $8.64 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

CapWealth Advisors LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,988 shares of the medical research company’s stock after buying an additional 350 shares during the quarter. CapWealth Advisors LLC’s holdings in Amgen were worth $8,637,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Moneta Group Investment Advisors LLC raised its position in shares of Amgen by 83,875.6% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Norges Bank bought a new stake in Amgen during the fourth quarter worth $1,351,778,000. Price T Rowe Associates Inc. MD grew its holdings in Amgen by 158.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after buying an additional 1,806,456 shares in the last quarter. International Assets Investment Management LLC bought a new position in Amgen in the 4th quarter valued at $4,589,900,000. Finally, Morgan Stanley grew its stake in Amgen by 12.9% in the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AMGN shares. StockNews.com downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. TD Cowen cut their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday. Daiwa Capital Markets upgraded Amgen from a “neutral” rating to a “buy” rating and increased their price target for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Finally, Raymond James initiated coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Trading Up 0.0 %

Shares of AMGN traded up $0.03 during mid-day trading on Thursday, hitting $264.10. 534,393 shares of the company’s stock traded hands, compared to its average volume of 2,831,060. The firm has a market capitalization of $141.54 billion, a P/E ratio of 21.14, a PEG ratio of 2.47 and a beta of 0.58. The business’s 50-day moving average price is $277.99 and its 200-day moving average price is $281.37. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the prior year, the firm earned $4.09 earnings per share. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, sell-side analysts forecast that Amgen Inc. will post 19.46 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.